Skip Navigation

   

Depression in Alzheimer's Disease Study - Phase 2 (DIADS-2)

The Depression in Alzheimer’s Disease Study-2 is a randomized, placebo-controlled, multi-center trial designed to evaluate the efficacy and safety of sertraline for the treatment of depression in patients with Alzheimer’s disease.

Sertraline was tested in parallel at a target dose of 100 mg per day (range 25-125 mg) against a matched placebo.The trial enrolled 131 participants who met NIMH criteria for “Depression of Alzheimer’s Disease.” Participants will be evaluated with structured, standardized methods of diagnosis and assessment.

Publications

Study Website

ClinicalTrials.gov Listing

 

© 2016, Johns Hopkins University. All rights reserved.
Web policies, 615 N. Wolfe Street, Baltimore, MD 21205